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OBJECTIVES: Payers in the U.S. are increasingly employing aggressive cost sharing 
strategies for specialty drugs. We conducted a systematic review of the published 
evidence on the associations between patient cost sharing and use of specialty drugs, 
use of non-drug medical services, and health outcomes and spending. METHODS: A 
MEDLINE search for U.S.-based studies published in English between 1995 and 2013 
was conducted using various combinations of terms for cost sharing and specialty 
drugs and/or common conditions for which they are indicated. Additional studies 
were obtained from reference lists of identified studies. Key methodological elements 
of the included studies were extracted and findings were captured to determine 
effects of cost sharing. RESULTS: We identified 15 articles that focused on one or more 
diseases, including MUltiple Sclerosis (n= 8), cancer (n= 7), Rheumatoid Arthritis (n= 5), 
and other conditions (n= 4). Majority of the studies (n= 14) used administrative claims 
data on privately insured patients from the year 2009 or earlier, during which time few 
private insurers were employing aggressive cost sharing for specialty drugs. Outcomes 
included prescription abandonment (n= 2), initiation or any utilization (n= 7), adher-
ence (n= 8), persistence/discontinuation (n= 6), number of claims (n= 1), and drug 
spending (n= 1). Findings generally indicated reductions in specialty drug utilization 
associated with higher cost sharing. However, the evidence was not consistent; the 
magnitude and/or statistical significance of the effects of cost sharing varied by dis-
ease and type of outcome. None of the studies examined the effect of specialty tier 
cost sharing seen under Medicare Part D or health insurance exchanges; or the effect 
of cost sharing on medical utilization, spending, or health outcomes. CONCLUSIONS: 
Evidence till date generally indicates reductions in specialty drug utilization associ-
ated with higher cost sharing, with effects varying by type of disease and specialty 
drug outcome. We draw upon our findings and the gaps in evidence to summarize 
future directions for research and policy.
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OBJECTIVES: The impact of health economics and outcomes research (HEOR) 
evidence on reimbursement decisions in the U.S. is not well understood, yet the 
continued and increasing investment in HEOR by pharmaceutical companies indi-
cates a perceived positive impact. We sought to understand U.S. payers’ prefer-
ences for HEOR evidence when making reimbursement decisions and to assess 
the alignment between payers and pharmaceutical companies with respect to the 
types of HEOR evidence that are important for various product and market sce-
narios. METHODS: We conducted an online, stated choice survey with individuals 
involved in the formulary decision-making process for U.S. payer and pharmacy 
benefit manager (PBM) organizations and those involved in the decision to invest 
in HEOR for pharmaceutical companies. We presented each individual with thirteen 
product profiles and asked them to rate the importance of several types of HEOR 
evidence to support U.S. formulary placement decisions for each profile. We used 
a logistic regression model to assess the product and market attributes that are 
associated with the stated importance of each type of evidence and to compare 
the alignment between respondents from pharmaceutical and payer/PBM organi-
zations. RESULTS: We received 31 responses from payers and 63 responses from 
individuals within pharmaceutical companies. Preliminary results indicate differ-
ences between the two stakeholder groups in the perceived importance of budget 
impact, resource utilization/cost offset, and adherence/compliance evidence. We 
report the most influential factors in the types of HEOR evidence that are stated 
to have an impact on formulary decision-making. CONCLUSIONS: The findings of 
this survey provide us with a better understanding of the specific types of HEOR 
evidence payers are interested in for pharmaceutical products entering the market. 
This nuanced understanding of payer preferences may allow for greater alignment 
between payer organizations and pharmaceutical companies, and will assist phar-
maceutical companies in planning future investments.
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OBJECTIVES: The Californian Technology Assessment Forum (CTAF) publishes 
reports that make recommendations on the comparative clinical effectiveness and 
value of medical interventions. The recommendations of CTAF, which is managed 
by the Institute for Clinical and Economic Review and funded by Blue Shield of 
California, are not binding and they do not determine health plan benefit coverage. 
In April 2014, CTAF gained a degree of public attention when they recommended 
that the Hepatitis C virus (HCV) treatments OLYSIO and SOVALDI be only used 
immediately in patients with advanced liver disease or those awaiting transplants 
based on a report including cost-utility economic modelling. This research aimed 
to systematically analyse all CTAF reports to determine what types of health 
technologies they assess, how restrictive their recommendations are, and how 
this has evolved over time. METHODS: All publically available CTAF reports were 
extracted and their date, indication, technology type, and recommendation were 
extracted. RESULTS: CTAF have issued 119 medical technologies appraisals since 
October 2002. 26/119 (22%) were recommended, 18/119 (15%) received restricted 
recommendations, and 75/119 (63%) not recommended. 33/119 appraisals (28%) 
were for diagnostic tests, 28/119 devices (24%), 27/119 (23%) surgery, 25/117 (21%) 
radio/radiation/laser-based emission therapies, 3/117 (3%) other, and only 3/117 
(3%) branded drugs. The branded drug submissions were for Avastin in metastatic 
OBJECTIVES: Biologic agents represent significant medical advances for rheumatoid 
arthritis (RA), and multiple sclerosis (MS). Yet, specialty tiers under the initial cover-
age limit (ICL) period of Medicare Part D require a coinsurance of up to 33% for such 
drugs. This study is the first to examine the impact of cost-sharing increases faced 
with specialty tiers on adherence and discontinuation among Medicare patients 
using RA and MS biologics. METHODS: This quasi-experimental study examined 
changes in outcomes across the Part D catastrophic coverage period in the previous 
year (pre-period) and the ICL period in the current year (post-period) for patients 
not receiving low-income subsidies (non-LIS) who faced coinsurance levels of 5% in 
the pre-period and 25%-33% in the post-period compared to a control group of LIS 
patients who faced the same cost-sharing ($5 copay) in the pre- and post-periods. 
Using the 2006-2010 5% Medicare files we identified patients with MS (ICD-9-CM 340.
xx) and RA (ICD-9-CM 714.xx) with continuous fee-for-service and Part D coverage 
and use of Part D biologics indicated for MS (N= 1887) and RA (N= 1982), respec-
tively, during the pre-period. Outcomes included adherence (proportion of days 
covered> = 0.8) and discontinuation (continuous 30-day gap) for Part D-covered, Part 
B-covered, and all biologics. GEE logit regressions adjusting for patient demograph-
ics and clinical severity and Part D plan formulary characteristics were estimated. 
Patient-level fixed-effects models were used in sensitivity analyses. RESULTS: 
The substantial increase in cost sharing under specialty tiers was associated with 
lower adherence (MS:OR= 0.56,p< 0.001; RA:OR= 0.50,p< 0.001) and higher likelihood 
of having gaps in Part D biologic (MS:OR= 1.56,p< 0.001; RA:OR= 2.73,p< 0.001) among 
non-LIS compared to LIS patients. Overall biologic use also declined due to limited 
substitution with Part B biologics in non-LIS patients. Sensitivity analyses showed 
consistent findings. CONCLUSIONS: The increased cost sharing under specialty 
tiers was associated with a decline in adherence and increase in discontinuation 
of MS and RA biologics.
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OBJECTIVES: A key portion of the Affordable Care Act’s new coverage, particu-
larly for chronic disease, is the prescription drug benefit. Each plan’s generos-
ity will depend on the particular mix of drugs for a given patient, not just the 
benefit structure. For a market basket of drugs, we assess the generosity of drug 
coverage for the four metal tiers in the Federally Facilitated health insurance 
exchanges. METHODS: We examined the 27 federally facilitated exchanges and 
7 partnership exchanges, for which characteristics of all plans on the exchanges 
were publicly available from data.gov for 2014. These files, however, do not contain 
drug formulary data, so we also use a unique data source of drug formulary data, 
from Managed Markets Insight & Technology. We were able to identify a total 
of 2,826 unique plan-formulary combinations with formulary and price data for 
21 drugs in these therapeutic areas. For each drug, we collected the price for a 
standard prescription fill from drugs.com, which allowed us to convert coinsur-
ance rates into prices. We then created a generosity index as the ratio of the 
out-of-pocket payment to the price of the drug. RESULTS: For individuals with 
higher out-of-pocket spending, there is considerable variation in the generosity 
of prescription drug coverage in all metal tiers. Comparisons by plan type indicate 
that PPO plans provide more generous prescription drug coverage, except in the 
bronze tier, for which HMO plans are significantly more generous than PPO plans 
until individuals have spent $5,000, or more, out of pocket. CONCLUSIONS: Given 
the substantial variation in generosity of drug coverage, consumers may have 
trouble finding the plan that best balances their ability to pay premiums, toler-
ance for financial risk, and preferences between prescription drug and all other 
costs.
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OBJECTIVES: A “biosimilar” is a biological medicine similar to a licensed biologi-
cal medicine (“originator”). As of October 2014, six biosimilars are licensed and 
marketed in Great Britain (GB) (three biosimilar filgrastims, two biosimilar epo-
etins and one biosimilar somatropin). Biological medicines are highly costly to 
the NHS, so it is expected that biosimilars will have an increasing presence as a 
cost-saving mechanism. This study explored the uptake of biosimilars within GB 
formularies. METHODS: Websites of acute trusts in England and health boards in 
Scotland and Wales were searched for the most recent drug formularies. The pres-
ence of biosimilars in a formulary was examined for all six products. Formularies 
that listed at least one biosimilar were considered to have a positive recognition 
of these products. RESULTS: Of 158 acute trusts in England and 21 health boards 
in Scotland and Wales, 176 websites were available, providing 144 formularies 
(England: 127, Scotland: 9; Wales: 7; England/Scotland shared: 1). 17 formular-
ies were shared across trusts and boards. At least one biosimilar was listed in 
63 formularies. While 45 formularies listed at least one biosimilar filgrastim, 31 
and 17 formularies listed biosimilar somatropin and epoetin, respectively. Five 
formularies listed at least one biosimilar from each of the three classes, 20 for-
mularies listed at least one from two classes, and 38 formularies listed at least 
one from only one class. In 19 formularies, at least one biosimilar was listed in 
preference to an originator product as first line therapy (filgrastim: 16; somatro-
pin: 5; epoetin: 1). CONCLUSIONS: The results of this survey suggest that 44% of 
formularies in Great Britain list at least one biosimilar, and in 30% of these, these 
are listed in preference to the originator product. This appears to be a low level 
of penetration into formularies given that these biosimilars have been available 
for over five years.
